RESUMO
Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the United States population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine will be reviewed, emphasizing treatment recommendations and the role of dermatologists in monitoring and educating patients regarding benefits as well as risks that may be associated. This guideline will also address the severity assessment methods of psoriasis in adults.
Assuntos
Terapias Complementares/métodos , Fármacos Dermatológicos/administração & dosagem , Dermatologia/métodos , Psoríase/terapia , Academias e Institutos/normas , Administração Cutânea , Terapia Combinada/métodos , Terapia Combinada/normas , Terapias Complementares/normas , Dermatologia/normas , Medicina Baseada em Evidências/métodos , Medicina Baseada em Evidências/normas , Fundações/normas , Humanos , Educação de Pacientes como Assunto/normas , Psoríase/diagnóstico , Índice de Gravidade de Doença , Resultado do Tratamento , Estados UnidosRESUMO
Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children, with onset most common during adolescence. This guideline addresses important clinical questions that arise in psoriasis management and provides evidence-based recommendations. Attention will be given to pediatric patients with psoriasis, recognizing the unique physiology, pharmacokinetics, and patient-parent-provider interactions of patients younger than 18 years old. The topics reviewed here mirror those discussed in the adult guideline sections, excluding those topics that are irrelevant to, or lack sufficient information for, pediatric patients.
Assuntos
Produtos Biológicos/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Metotrexato/uso terapêutico , Fotoquimioterapia , Psoríase/tratamento farmacológico , Psoríase/epidemiologia , Adolescente , Corticosteroides/uso terapêutico , Antralina/uso terapêutico , Inibidores de Calcineurina/uso terapêutico , Doenças Cardiovasculares/epidemiologia , Criança , Pré-Escolar , Alcatrão/uso terapêutico , Comorbidade , Ciclosporina/uso terapêutico , Dislipidemias/epidemiologia , Medicina Baseada em Evidências , Humanos , Lactente , Recém-Nascido , Doenças Inflamatórias Intestinais/epidemiologia , Resistência à Insulina , Saúde Mental , Síndrome Metabólica/epidemiologia , Ácidos Nicotínicos/uso terapêutico , Obesidade/epidemiologia , Psoríase/psicologia , Retinoides/uso terapêuticoRESUMO
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).
Assuntos
Psoríase/tratamento farmacológico , Acitretina/uso terapêutico , Ciclosporina/uso terapêutico , Monitoramento de Medicamentos , Humanos , Metotrexato/uso terapêutico , Piperidinas/uso terapêutico , Pirimidinas/uso terapêutico , Talidomida/análogos & derivados , Talidomida/uso terapêuticoRESUMO
Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations on the basis of available evidence.
Assuntos
Doenças Cardiovasculares/epidemiologia , Saúde Mental , Síndrome Metabólica/epidemiologia , Obesidade/epidemiologia , Papel do Médico , Psoríase/epidemiologia , Psoríase/psicologia , Qualidade de Vida , Artrite Psoriásica/diagnóstico , Artrite Psoriásica/epidemiologia , Comorbidade , Dislipidemias/epidemiologia , Medicina Baseada em Evidências , Humanos , Hipertensão/epidemiologia , Doenças Inflamatórias Intestinais/epidemiologia , Nefropatias/epidemiologia , Estilo de Vida , Hepatopatias/epidemiologia , Pneumopatias Obstrutivas/epidemiologia , Neoplasias/epidemiologia , Educação de Pacientes como Assunto , Psoríase/terapia , Síndromes da Apneia do Sono/epidemiologiaRESUMO
Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks.
Assuntos
Produtos Biológicos/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Psoríase/tratamento farmacológico , Adalimumab/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Medicamentos Biossimilares/uso terapêutico , Certolizumab Pegol/uso terapêutico , Quimioterapia Combinada , Etanercepte/uso terapêutico , Medicina Baseada em Evidências , Humanos , Infliximab/uso terapêutico , Piperidinas/uso terapêutico , Pirimidinas/uso terapêutico , Pirróis/uso terapêutico , Ustekinumab/uso terapêuticoRESUMO
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world's population. In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light-based therapies, which include narrowband and broadband UVB, UVA in conjunction with photosensitizing agents, targeted UVB treatments such as with an excimer laser, and several other modalities and variations of these core phototherapies, including newer applications of pulsed dye lasers, intense pulse light, and light-emitting electrodes. We will provide an in-depth, evidence-based discussion of efficacy and safety for each treatment modality and provide recommendations and guidance for the use of these therapies alone or in conjunction with other topical and/or systemic psoriasis treatments.
Assuntos
Dermatologia/normas , Fototerapia/normas , Guias de Prática Clínica como Assunto , Psoríase/terapia , Academias e Institutos/normas , Fundações/normas , Humanos , Metanálise como Assunto , Fototerapia/instrumentação , Fototerapia/métodos , Revisões Sistemáticas como Assunto , Resultado do Tratamento , Estados UnidosRESUMO
Acne is one of the most common disorders treated by dermatologists and other health care providers. While it most often affects adolescents, it is not uncommon in adults and can also be seen in children. This evidence-based guideline addresses important clinical questions that arise in its management. Issues from grading of acne to the topical and systemic management of the disease are reviewed. Suggestions on use are provided based on available evidence.